⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7361822 | 0.71 | — | — | |
| SCHEMBL935229 | 0.70 | — | — | |
| SCHEMBL14859078 | 0.70 | — | — | |
| SCHEMBL723777 | 0.70 | — | — | |
| SCHEMBL392829 | 0.70 | — | — | |
| SCHEMBL935566 | 0.70 | — | — | |
| SCHEMBL935675 | 0.70 | — | — | |
| SCHEMBL28258686 | 0.70 | — | — | |
| SCHEMBL14771286 | 0.69 | CHEK1 (0.49) | — | |
| SCHEMBL13619043 | 0.69 | PDE3B (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132121-A1 | INHIBITORS OF RIPK2 AND MEDICAL USES THEREOF | ODYSSEY THERAPEUTICS INC (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4622970-A1 | INHIBITORS OF RIPK2 AND MEDICAL USES THEREOF | ODYSSEY THERAPEUTICS, INC. (US) | 2025-10-01 | — | — | EP | disclosed |
| EP-4568666-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Alexion Pharmaceuticals, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| WO-2025106863-A1 | LACTAM DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF | VENTUS THERAPEUTICS U.S., INC. (US) | 2025-05-22 | — | — | WO | disclosed |
| CN-119768164-A | Pharmaceutical compounds for treating complement-mediated disorders | 阿雷克森制药公司 | 2025-04-04 | — | — | CN | disclosed |
| US-20250011323-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-01-09 | — | — | US | disclosed |
| US-20240391917-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2024-11-28 | — | — | US | disclosed |
| US-12110288-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2024-10-08 | — | — | US | disclosed |
| US-20240217951-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-07-04 | — | — | US | disclosed |
| WO-2024112854-A1 | INHIBITORS OF RIPK2 AND MEDICAL USES THEREOF | ODYSSEY THERAPEUTICS, INC. (US) | 2024-05-30 | — | — | WO | disclosed |
| EP-1079835-A4 | PYRAZINONE THROMBIN INHIBITORS | MERCK & CO INC (US) | 2002-10-29 | — | — | EP | disclosed |
| US-6455532-B1 | ANTICOAGULANTS | MERCK & CO., INC. | 2002-09-24 | — | — | US | disclosed |
| US-6417203-B1 | HETEROCYCLIC AMIDES | PFIZER INC. | 2002-07-09 | — | — | US | disclosed |
| CN-1353705-A | Pyrazinone thrombin inhibitors | MERCK & CO INC (US) | 2002-06-12 | — | — | CN | disclosed |
| EP-1189899-A1 | PYRAZINONE THROMBIN INHIBITORS | Merck & Co., Inc. (US) | 2002-03-27 | — | — | EP | disclosed |
| EP-1079835-A1 | PYRAZINONE THROMBIN INHIBITORS | Merck & Co., Inc. (US) | 2001-03-07 | — | — | EP | disclosed |
| US-6180627-B1 | INDOLE, INDAZOLE, BENZOTRIAZOLE AND BENZIMIDAZOLE DERIVATIVES | PFIZER INC. | 2001-01-30 | — | — | US | disclosed |
| WO-2000075134-A1 | PYRAZINONE THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2000-12-14 | — | — | WO | disclosed |
| EP-0997474-A1 | Antithrombotic agents | PFIZER INC. (US) | 2000-05-03 | — | — | EP | disclosed |
| WO-1999059591-A1 | PYRAZINONE THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 1999-11-25 | — | — | WO | disclosed |